# Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication

> **NCT01805531** · — · COMPLETED · sponsor: **Bayer** · enrollment: 411 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)

## Key facts

- **NCT ID:** NCT01805531
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2015-01
- **Final completion:** 2015-03
- **Target enrollment:** 411 (ACTUAL)
- **Last updated:** 2017-01-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01805531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01805531, "Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01805531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*